HTRA inhibitors
- 總結
- Novel Ahp-cyclodepsipeptide-based HTRA inhibitors for the treatment of macular degeneration (HTRA1) or cell death in reperfusion-ischemia (HTRA2).
- 技術優勢
- First-in-class inhibitors for HTRA
Novel promising drug target for various indications
- 技術應用
- Ahp-cyclodepsipeptides constitute a novel class of HTRA inhibitors and are thus qualified to be further developed as “first-in-class” drugs for that target.
- 詳細技術說明
- Ahp-cyclodepsipeptides represent a suitable scaffold for generating target-tailored inhibitors of serine proteases. They have developed a practical mixed solid- and solution-phase synthesis that allows the customized synthesis of Ahp-cyclodepsipeptides and thus tailored inhibitor synthesis.
- 合作類型
- Licensing
- 申請日期
- 14/05/2018 00:00:00
- 申請號碼
- WO2018EP62381 20180514
- 分類
- - international:
C07K7/06; C07K7/54
- cooperative:
C07K11/00; C12Q1/37; A61K38/00; G01N2500/04
- 其他
- Patent application
- ID號碼
- 4907
- 國家/地區
- 德國
欲了解更多信息，請點擊 這裡
